{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:17:20Z","timestamp":1785237440806,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,3]],"date-time":"2020-05-03T00:00:00Z","timestamp":1588464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.lungcan.2020.04.036","type":"journal-article","created":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T16:10:19Z","timestamp":1588608619000},"page":"27-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Image-based ex vivo drug screen to assess targeted therapies in recurrent thymoma"],"prefix":"10.1016","volume":"145","author":[{"given":"Antti","family":"Arjonen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"M\u00e4kel\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ville","family":"H\u00e4rm\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Rintanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teijo","family":"Kuopio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha","family":"Kononen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha K.","family":"Rantala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2020.04.036_bib0005","first-page":"236","article-title":"Reproducibility of the WHO classification of thymomas: practical implications","volume":"79","author":"Zucali","year":"2013","journal-title":"Lung Can."},{"key":"10.1016\/j.lungcan.2020.04.036_bib0010","article-title":"Thymoma in myasthenia gravis: from diagnosis to treatment","volume":"2011","author":"Romi","year":"2011","journal-title":"Autoimmune Dis."},{"issue":"Suppl 2","key":"10.1016\/j.lungcan.2020.04.036_bib0015","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/JTO.0000000000000290","article-title":"The IASLC\/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors","volume":"9","author":"Detterbeck","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.04.036_bib0020","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s11864-009-0084-6","article-title":"The World Health Organization (WHO) histologic classification of thymomas: a reanalysis","volume":"9","author":"Moran","year":"2008","journal-title":"Curr. Treat. Options Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2020.04.036_bib0025","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/ejcts\/ezy448","article-title":"Report from the European society of thoracic surgeons prospective thymic database 2017: a powerful resource for a collaborative global effort to manage thymic tumours","volume":"55","author":"Ruffini","year":"2019","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.lungcan.2020.04.036_bib0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejcts.2009.05.038","article-title":"Thymoma and thymic carcinoma","volume":"37","author":"Venuta","year":"2010","journal-title":"Eur J. CardioThorac Surg Off J Eur Assoc Cardio-Thorac Surg"},{"issue":"2","key":"10.1016\/j.lungcan.2020.04.036_bib0035","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0022-5223(96)70265-9","article-title":"Prognostic factors and long-term results after thymoma resection: a series of 307 patients","volume":"112","author":"Regnard","year":"1996","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"3","key":"10.1016\/j.lungcan.2020.04.036_bib0040","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0003-4975(03)00555-1","article-title":"Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan","volume":"76","author":"Kondo","year":"2003","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.lungcan.2020.04.036_bib0045","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2010.32.4467","article-title":"Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors","volume":"29","author":"Giaccone","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2020.04.036_bib0050","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/JCO.2017.74.4078","article-title":"Phase II study of Everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy","volume":"36","author":"Zucali","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2020.04.036_bib0055","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1470-2045(07)70141-9","article-title":"Response of thymoma to cetuximab","volume":"8","author":"Farina","year":"2007","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2020.04.036_bib0060","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol."},{"issue":"24","key":"10.1016\/j.lungcan.2020.04.036_bib0065","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2020.04.036_bib0070","doi-asserted-by":"crossref","first-page":"5867","DOI":"10.21873\/anticanres.13791","article-title":"Clonal evolution of MEK\/MAPK pathway activating mutations in a metastatic colorectal Cancer case","volume":"39","author":"Lehtomaki","year":"2019","journal-title":"Anticancer Res."},{"issue":"4","key":"10.1016\/j.lungcan.2020.04.036_bib0075","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.eururo.2019.06.016","article-title":"Personalized drug sensitivity screening for bladder Cancer Using conditionally reprogrammed patient-derived cells","volume":"76","author":"Kettunen","year":"2019","journal-title":"Eur J Urol"},{"issue":"2","key":"10.1016\/j.lungcan.2020.04.036_bib0080","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1016\/S1470-2045(15)00396-4","article-title":"Research methods to change clinical practice for patients with rare cancers","volume":"17","author":"Billingham","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2020.04.036_bib0085","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nmeth.3853","article-title":"Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs","volume":"13","author":"Hafner","year":"2016","journal-title":"Nat. Methods"},{"key":"10.1016\/j.lungcan.2020.04.036_bib0090","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nbt.3882","article-title":"Alternative drug sensitivity metrics improve preclinical cancer pharmacogenomics","volume":"35","author":"Hafner","year":"2017","journal-title":"Nat. Biotechnol."},{"issue":"Suppl 2","key":"10.1016\/j.lungcan.2020.04.036_bib0095","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/JTO.0000000000000297","article-title":"Histologic classification of thymoma: a practical guide for routine cases","volume":"9","author":"den Bakker","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.04.036_bib0100","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/modpathol.2009.105","article-title":"Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms","volume":"10","author":"Kojika","year":"2009","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.lungcan.2020.04.036_bib0105","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1746-1596-2-13","article-title":"Thymomas: a cytological and immunohistochemical study, with emphasis on lymphoid and neuroendocrine markers","volume":"2","author":"Alexiev","year":"2007","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.lungcan.2020.04.036_bib0110","doi-asserted-by":"crossref","DOI":"10.1038\/sdata.2017.166","article-title":"Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics","volume":"4","author":"Hafner","year":"2017","journal-title":"Sci. Data"},{"issue":"4","key":"10.1016\/j.lungcan.2020.04.036_bib0115","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1158\/1078-0432.CCR-09-2353","article-title":"AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer","volume":"16","author":"Hickinson","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.lungcan.2020.04.036_bib0120","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/nm1146","article-title":"Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors","volume":"10","author":"Issaeva","year":"2004","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.lungcan.2020.04.036_bib0125","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/his.13936","article-title":"A mutation analysis of the EGFR pathway genes, RAS, EGFR, PIK3CA, AKT1 and BRAF, and TP53 gene in thymic carcinoma and thymoma type A\/B3","volume":"75","author":"Sakane","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.lungcan.2020.04.036_bib0130","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2741\/2098","article-title":"Cetuximab is an active treatment of metastatic and chemorefractory thymoma","volume":"12","author":"Palmieri","year":"2007","journal-title":"Front Biosci"},{"key":"10.1016\/j.lungcan.2020.04.036_bib0135","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1470-2045(07)70141-9","article-title":"Response of thymoma to cetuximab","volume":"8","author":"Farina","year":"2007","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2020.04.036_bib0140","doi-asserted-by":"crossref","first-page":"19087","DOI":"10.1200\/jco.2008.26.15_suppl.19087","article-title":"A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma","volume":"26","author":"Bedano","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2020.04.036_bib0145","doi-asserted-by":"crossref","first-page":"674","DOI":"10.5761\/atcs.cr.13-00141","article-title":"Does gefitinib have effects on EGFR mutation-positive thymoma? Case report of thymoma recurrence","volume":"20","author":"Nakagiri","year":"2014","journal-title":"Ann. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.lungcan.2020.04.036_bib0150","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/icvts\/ivv040","article-title":"Do thymic malignancies respond to target therapies?","volume":"20","author":"Hu","year":"2015","journal-title":"Interact. Cardiovasc. Thorac. Surg."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220304074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220304074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:39:31Z","timestamp":1759235971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500220304074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":30,"alternative-id":["S0169500220304074"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.04.036","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Image-based ex vivo drug screen to assess targeted therapies in recurrent thymoma","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.04.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}